SuperworthAlamar Biosciences EPS ALMR
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.22
Alamar Biosciences' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.22.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$0.22 | n/a | |
| Q1 FY26 | −$1.74 | n/a | |
| Q2 FY25 | −$0.62 | n/a | |
| Q1 FY25 | −$0.68 | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Alamar Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ALMRAlamar Biosciences | n/m | |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| LNTHLantheus | $4.13 | +10% a year |
| CAICaris Life Sciences | $0.37 | |
| NRCNRC Health | $0.25 | −67% a year |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Alamar Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.